A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with
Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as Induction Therapy
and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in
Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma.
OBJECTIVES:
The primary objective is to evaluate the safety and tolerability of Tec-DRd and Tec-DVRd as
induction therapy and Tec-DR as post-transplant maintenance therapy in participants with
ND-TEMM.
The key secondary objective is to evaluate the efficacy of Tec-DRd and Tec-DVRd as induction
therapy and Tec-DR as post-transplant maintenance therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Heidelberg Medical Center
Collaborators:
Deutsche Studiengruppe Multiples Myelom (DSMM) Janssen Research & Development, LLC